Teva’s ~7x P/E Multiple – Earnings Insight
Image Source: Teva Let’s cover some ground on Teva Pharma’s (TEVA) third-quarter report. By Brian Nelson, CFA What management said: “This has been a year of transition for Teva, underscored this quarter by the close of our strategic acquisition of Actavis Generics, which had significant contribution to our results. Actavis will continue to contribute in a meaningful way to the future growth of our generics business through the strengthened R&D capabilities and complementary pipeline and portfolio, and enhance our leadership in an increasingly evolving industry,” stated Erez Vigodman, Teva’s President and CEO. “We were also pleased to report this quarter that we have successfully completed the second pivotal phase three study for SD-809 for tardive dyskinesia and plan to submit … Read more